Evaluation of fibrinogen level among Sudanese women who use contraceptive implant in Khartoum state
1 Department of Hematology and blood bank, Faculty of Medical Laboratory Science, Alzaiem Alazhari University, Khartoum, Sudan.
2 Department of Hematology and blood bank, Faculty of Medical Laboratory Science, Riyadh International College, Khartoum, Sudan.
3 Departments of Hematology and blood transfusion, Faculty of medical laboratory sciences, Alzaeim Alazhari-University-khartoum-Sudan.
4 Department of Hematology and blood bank, faculty of medical laboratory sciences, Hayatt Universitycollege, Khartoum-Sudan.
5 Departments of Hematology and blood transfusion, Faculty of medical laboratory sciences, Mashreq-University-khartoum-Sudan.
Research Article
International Journal of Biological and Pharmaceutical Sciences Archive, 2025, 10(02), 094–100.
Article DOI: 10.53771/ijbpsa.2025.10.2.0085
Publication history:
Received on 07 October 2025; revised on 15 November 2025; accepted on 17 November 2025
Abstract:
Background: Fibrinogen, a key protein in coagulation, plays a crucial role in hemostasis and thrombotic disorders. Contraceptive implant use is associated with increased fibrinogen levels, potentially contributing to a hypercoagulable state and elevated thrombotic risk. Objectives: This study is aimed to evaluate and compare fibrinogen levels among women using contraceptives implant and non-users.
Materials and Methods: Descriptive, Case Control study was conducted at Khartoum state between October and December 2024 with 100 participants divided equally into cases (contraceptive users) and controls (non-users). Fibrinogen levels were measured by Clauss method and analyzed using SPSS.
Results: The mean fibrinogen level was significantly higher in the case group (462 ± 31.3 mg/dL) compared to the control group (281 ± 39.2 mg/dL), with a p-value <0.001, indicating a statistically significant difference. When analyzed by age, the mean fibrinogen levels were (438.2 ± 12.2 mg/dL) for participants aged 22–30 years and (471.4 ± 10.1 mg/dL) for those aged 31–40 years, indicating that increase in age it associated with increase in fibrinogen levels this difference was statistically significant (p = 0.04). The duration of contraceptive implants use had a marked Impact on fibrinogen levels. Women who had used contraceptive implants for 1–2 years had a mean fibrinogen level of (429.8 ± 16.8 mg/dL), whereas those with a usage duration exceeding two years had a significantly higher mean fibrinogen level of (459.3 ± 17.5 mg/dL) (p = 0.03), suggesting that prolonged contraceptive implants use is associated with an increase in fibrinogen levels.
Conclusion: Contraceptive implants use, is associated with increase fibrinogen levels, also contraceptive implants use is association with increase fibrinogen levels depending on increase age and duration, indicating a higher thrombotic risk.
Keywords:
Fibrinogen level; Women fibrinogen level; Contraceptive implant; Women implant; Contraceptive use
Full text article in PDF:
Copyright information:
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0